Back

From reduced to normal left ventricular ejection fraction: what makes a super-responder to CRT?

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in arrhythmias and device therapy 8 Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Luisa Pinheiro

Unidade Local de Saude do Alto Ave, Guimaraes (Portugal)

6 More presentations in this session

Presentation thumbnail
The learning curve of left bundle branch area pacing: feasibility, safety, acute success rates and echocardiographic assessment of mechanical dyssynchrony
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Left bundle branch pacing versus biventricular pacing for cardiac resynchronization in patients with heart failure: single-centre experience.
Doctor I. Franco Fernandez (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Assessing the response to cardiac resynchronization therapy in heart failure patients: a comparative analysis between transvenous and epicardial leads.
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Comparing LV lead performance and procedure-related complications: transvenous vs epicardial leads in cardiac resynchronization therapy
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Differential outcomes of cardiac resynchronization therapy based on heart failure etiology
Doctor A. Ribeiro Teixeira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in arrhythmias and device therapy 8

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
CRT super responders: why they are so special and how to become one
thumbnail
Congress Presentation
Evaluating superresponse in CRT: a clinical edge or just a remodeling effect?
thumbnail
Congress Presentation
Re-classification of response to cardiac resynchronization therapy: the long-term effect of echocardiographic non-progression

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources